TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System
Panel votes unanimously in support of the OCS Liver System's safety and effectiveness
News provided by
Share this article
Share this article
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of TransMedics' clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Liver System.  

Related Keywords

Andover ,Massachusetts ,United States ,Waleed Hassanein ,Jamesf Markmann ,Transmedics Group Inc ,Drug Administration ,Advisory Committee ,Division Of Transplantation Surgery At Massachusetts ,Transmedics Group ,Urology Devices Panel ,Medical Devices Advisory Committee ,Chief Executive ,Transmedics Liver ,Transplantation Surgery ,Massachusetts General Hospital ,System Device Advisory Panel ,ஆண்டோவர் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,வாலீட் ஹஸ்ஸனேன் ,தலைமை நிர்வாகி ,மாற்று அறுவை சிகிச்சை அறுவை சிகிச்சை ,மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை ,